• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

    How Can Automation Optimize Immunohistochemistry?
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    Alcami

    Baxter BioPharma Solutions

    IDT Biologika

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Kyongbo Pharmaceutical

    Alcami

    Baxter BioPharma Solutions

    IDT Biologika

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Spray Drying: A Proven Approach to Enhance the Solubility of APIs

    Spray drying is an established particle engineering technology that offers several advantages over other methods used for improving API bioavailability.

    Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Figure 1. The Biopharmaceutics Classification System (BCS) as defined by the FDA after Amidon et al.
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Figure 2. The spray drying process.
    Related CONTENT
    • AmbioPharm, Inc.
    • Biosynth Carbosynth
    • Vio Chemicals
    • Aenova
    • WuXi AppTec
    Benzion Dolitzky, PhD, VP R&D, Wavelength Pharmaceuticals09.09.21
    Low aqueous solubility of active pharmaceutical ingredients (APIs) often translates to poor bioavailability that can be a cause of failure during drug development. For this reason, improved aqueous solubility is a primary objective of formulation development. Spray drying is an established particle engineering technology that has been widely used to enhance the solubility of oral, inhaled, and topical drugs. It involves producing dry powders from a fluid material by atomization into a hot drying gas medium, usually air or nitrogen.

    A main advantage of spray drying is its capacity for continuous operation that enables the implementation of process analytical technology to safeguard highly reproducible drug production. Spray drying is also faster, more cost-effective and easier to manage than many other particle engineering technologies, and is readily scalable, especially in the hands of an experienced API CDMO.

    Notably, with the number of poorly soluble small molecule drugs continuing to grow, the demand for spray drying capacity is on the rise and production slots are booked well in advance. While next generation spray drying technologies promise to help alleviate the bottleneck, Wavelength Pharmaceuticals continues to invest in both current and novel spray drying methodologies, to deliver on these strategic market needs. With spray drying expertise gained from more than 30 years of developing and manufacturing its own product portfolio Wavelength has invested in state-of-the-art equipment to support a wide range of manufacturing requirements, from small-scale clinical drug development projects through commercial-scale GMP production.

    Low aqueous solubility is a major problem
    Oral dosing represents the most convenient form of drug delivery and is commonly associated with high patient compliance. However, low aqueous solubility can be a major problem when developing oral dosage forms since it restricts drug absorption within the gastrointestinal tract to limit bioavailability. Low aqueous solubility can also present problems when developing inhaled drugs, or products that will be applied as topical, transdermal, or ophthalmic treatments. Addressing low aqueous solubility is therefore a primary objective of formulation development to help assure regulatory approval and bring urgently-needed therapeutics to patients.

    To rationalize formulation development, the Biopharmaceutics Classification System (BCS) categorizes drug substances according to aqueous solubility and permeability—the two main factors influencing drug absorption.
    Based on the BCS criteria, Class 1 drugs are characterized by high solubility and high permeability, Class 2 drugs by low solubility and high permeability, Class 3 drugs by high solubility and low permeability, and Class 4 drugs by low solubility and low permeability (Figure 1). Both Class 2 and Class 4 drugs are candidates for solubility enhancement.

    Formulation development addresses aqueous solubility
    Formulation development involves determining which excipients will be combined with the API in the final product to provide the delivery dosage form, whether that be solid, liquid, or semi-solid (e.g. a hydrogel). Critically, formulation development is where API aqueous solubility issues are best addressed, typically through designing different API salts, developing co-crystals, or through particle engineering.

    Although designing different API salts is a familiar approach, it is largely based on trial and error as the link between salt form and solubility is currently poorly understood. Moreover, because some APIs lack the functional groups required for salt formation, comparing different salts is not always a viable strategy. Co-crystallization overcomes this problem by combining the API and one or more co-formers in the same crystal lattice. It provides opportunities for developing solid-state forms other than conventional salts and polymorphs, and is also open to supramolecular engineering—the exploitation of supramolecular interactions such as Van der Waals forces, hydrogen bonding and electrostatic interactions to improve the physicochemical properties of the API.

    Particle engineering technologies include micronization, lyophilization and spray drying. Micronization functions to reduce the average particle diameter of a solid material through collisions with moving parts of the milling system (e.g., ball-milling, pin-milling, or hammer milling) or with itself (e.g., jet milling). A main drawback of this method is that the mechanical stresses it generates can cause local heating that may lead to melting, degradation, or structural defects; micronization also offers only limited control over key particle characteristics and has high associated material losses. Lyophilization and spray drying are more controllable and instead involve rapid drying of a liquid containing the dissolved API to generate an amorphous solid dispersion (ASD). Spray drying provides several important advantages over lyophilization, including elimination of the need for a post-drying milling step, as discussed below.

    Spray drying is an established solubility enhancement technology
    Spray drying has been successfully applied across multiple industries (predominantly the food and pharmaceutical industries) to convert a liquid feed into a powder. In drug manufacturing, it is an established particle engineering technology that involves dissolving the API in a solvent with one or more polymers (to prevent crystallization) and any necessary excipients, before injecting the mixture into a specialized spray dryer apparatus. As the liquid enters the spray dryer, it is atomized by a nozzle to form small, spherical droplets; these are then rapidly dried by a powerful blast of heated air (or nitrogen when working with organic solvents) within the spray drying chamber.
    Following any additional drying cycles, and particle separation in a cyclone, the resulting ASD is collected and can be used to manufacture the final drug product. The main objective of the spray drying process (Figure 2) is to transform the API into an ASD exhibiting improved solubility and physical stability compared to the parent material.

    Advantages of spray drying
    A major advantage of spray drying over other particle engineering technologies is its capacity to operate as a rapid, continuous process. This removes any limitations on batch size, as well as allowing for the implementation of process analytical technology to ensure reliable operation. Moreover, unlike technologies such as micronization and lyophilization, spray drying avoids the need for a milling step (during lyophilization, milling is occasionally required to convert the dried material into a fine powder) that can compromise the performance of thermolabile APIs or biologics that are sensitive to abrasion or shearing.

    Perhaps most importantly, spray drying provides tight control over critical product parameters such as particle size, density, and morphology; these can be fine-tuned by adjusting key process parameters or changing the sprayed solution composition to ensure consistent production of a high-quality product. Additionally, when compared directly with lyophilization, spray drying is more cost-effective and compatible with a broader range of solvents; these include both water-based solutions and class 3 solvents such as methanol, ethanol, acetone, and ethyl acetate, which can be recovered and recycled.

    Challenges of spray drying
    Despite being a leading technology to enhance drug solubility, spray drying requires an experienced operator to accurately control particle quality and yield. Factors that must be considered include the composition, concentration, and stability of the parent solution (both the drug and any polymers need to dissolve in the solvent system) and whether heating is required to decrease the viscosity of the feed; in this scenario, both the API and any excipients must be stable at high temperature.

    It is also important to select an appropriate nozzle. While pressure nozzle atomization may be more suitable where a larger average particle size is required, rotary nozzle atomization is often preferred for achieving a narrower particle size distribution (PSD), and multi-feed nozzles should be used where two or more liquids will be injected in parallel. Other considerations include whether the air/nitrogen should be blown from the bottom of the drying chamber or the top (the latter is frequently employed as a means of preventing over-heating), and the temperature at both the inlet and the outlet points, which is critical for producing stable particles and ensuring process robustness. The size of the spray dryer will be dictated by the required production scale; models range from benchtop size for initial development stages through larger commercial scale spray dryers capable of producing kilograms of material per hour.

    Partnering with an experienced API CDMO
    The effective use of spray drying for solving solubility and bioavailability challenges in drug manufacturing hinges on strong expertise in process design and development, as well as a robust working knowledge of all quality and regulatory requirements for GMP commercial production. Experience is also critical to establish early on whether a particular drug substance is an appropriate candidate for spray drying or more suitable for other bioavailability enhancing technologies, and to efficiently identify formulation conditions that provide the desired solubility, dissolution rate, content uniformity, and bioavailability. One way of accessing this knowhow is to partner with an API CDMO experienced in the use of spray drying for a broad range of drugs—including high potency APIs (HPAPIs)—and offering the right equipment, team and facilities for the job. 
    Suggested For You
    AmbioPharm, Inc. AmbioPharm, Inc.
    Biosynth Carbosynth Biosynth Carbosynth
    Vio Chemicals Vio Chemicals
    Aenova Aenova
    WuXi AppTec WuXi AppTec
    ViscoTec America Inc. ViscoTec America Inc.
    Scout Scientific LLC Scout Scientific LLC
    MedPharm MedPharm
    Sekisui Sekisui
    NGT BioPharma Consultants, LLC NGT BioPharma Consultants, LLC
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    LabVantage Solutions Launches LabVantage Enterprise SaaS LabVantage Solutions Launches LabVantage Enterprise SaaS
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies
    Samsung Biologics to Participate in Frontier 1.5D Initiative Samsung Biologics to Participate in Frontier 1.5D Initiative

    Related Content

    • AmbioPharm, Inc.

      ...
      Denise Karounos, Sr Marketing Manager 04.05.22

    • Biosynth Carbosynth

      Biosynth Carbosynth

      ...
      Aimee Cossins, Marketing 03.01.22

    • Vio Chemicals

      ...
      Ioanna Kazantzidou, Marketing Communications Officer 12.07.21


    • Aenova

      Aenova

      ...
      Susanne Knabe, Head of Communication & PR 11.30.21

    • WuXi AppTec

      ...
      Daja Herald, Marketing Director 11.22.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Pylon Coatings Uses Polygiene Biomaster & Verimaster for Antimicrobial Surface Protection
      Sto Corp. Recognized with Multiple Honors at the EIFS Hero Awards
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Hanmi Fine Chemical Launches CDMO Business
      DFE Pharma Opens India CoE for Fast-Track Formulation Services
      Helsinn Establishes New R&D Hub in the U.S.
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Carlyle To Acquire HCP Packaging
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Sonoco Announces Transition of Chief Financial Officer
      Azelis Expands Presence in India
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Zeller+Gmelin named Berry Global’s 2021 Ink Supplier of the Year
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login